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Human endothelial cellSignal transducer and activator of transcription 3 (STAT3) acts as a mediator and biomarker in endothelial
activation. We have recently shown that a novel adipokine visfatin promotes endothelial angiogenesis. The
present study was to determine whether visfatin affects STAT3 activity and to explore the potential target
gene(s). Here, we found that visfatin induced the activation of STAT3, as characterized by increased tyrosine
phosphorylation, nuclear translocation, and DNA-binding activity in human endothelial cells. In addition,
visfatin signiﬁcantly upregulated mRNA and protein levels of endothelial interleukin-6 (IL-6), which was
blocked by a speciﬁc inhibitor of STAT3 signaling and by the transfection of siRNA speciﬁc for STAT3.
Furthermore, visfatin-induced angiogenesis was reduced by the inhibition of STAT3 signaling or
neutralization of IL-6 function, as measured by tube formation, rat aortic ring assay, and mouse Matrigel
plug assay. Taken together, our results provide the ﬁrst example of STAT3-dependent endothelial IL-6
induction by visfatin and of the role of IL-6 in mediating visfatin-induced angiogenesis.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Angiogenesis, the formation of new capillary blood vessels from
existing microvessels, plays an important role in the process of
embryonic development, and in adult tissue maintenance or regen-
eration [1,2]. Aberrant angiogenesis contributes to vascular diseases,
including inﬂammation, atherosclerosis, tumor growth, and obesity
[3]. Angiogenesis is modulated by a number of both positive and
negative angiogenic factors with direct and indirect effects on
endothelial cells [4]. Adipokines, biologically active polypeptide
growth factors and cytokines that are mainly produced by adipose
tissue and involved in obesity [5], have been reported to induce local
and systemic angiogenesis [6].
Visfatin (also known as pre-B-cell colony-enhancing factor, PBEF),
a highly conserved 52-kDa protein, is a novel adipokine that strongly
correlates with visceral obesity [7,8]. We and others have previously
demonstrated that visfatin has angiogenic activity in in vitro, ex vivo,
and in vivo assays [9-11] and that visfatin upregulates the expressionool of Medicine, Pusan National
10 8074; fax: +82 51 510 8076.
ll rights reserved.of FGF-2 and VEGF genes, leading to endothelial angiogenesis [11,12].
Thus, these results strongly indicate that visfatin acts as a pro-
angiogenic adipokine via increasing levels of other angiogenic factors.
Interleukin-6 (IL-6), a multifunctional cytokine [13], induces
angiogenesis ex vivo and in vivo [14]. In addition, in vitro studies
have shown that IL-6 is capable to increase endothelial permeability
and stimulates the proliferation of endothelial cells [15]. The levels of
IL-6 are highly elevated in diseases that show dysregulated angio-
genesis including arthritis, atherosclerosis, diabetes, cancer, and
obesity [16,17], suggesting the importance of clarifying the mechan-
isms of IL-6 gene induction for therapeutic application against these
vascular diseases.
So far, several nuclear transcription factors such as NF-IL6, AP1,
and NF-kB have been reported to contribute to IL-6 gene induction
[18]. For example, IL-1 and tumor necrosis factor alpha (TNF-α)
induce IL-6 gene expression via NF-kB activation [19]. Recently, signal
transducer and activator of transcription 3 (STAT3)was demonstrated
tomediate IL-6 gene induction by phosphatidic acid and cardiotropin-
1 in macrophage and human endothelial cells, respectively [20,21].
Moreover, studies have demonstrated the role of STAT3 as a mediator
and biomarker in endothelial activation [22].
Here, we attempted to determine whether IL-6 gene expression is
affected by visfatin in human endothelial cells, and to characterize the
1760 J.-Y. Kim et al. / Biochimica et Biophysica Acta 1793 (2009) 1759–1767mechanisms involved. We report for the ﬁrst time that visfatin
induces the activation of STAT3 upstream of IL-6 expression to induce
angiogenesis (visfatin/STAT3/IL-6/angiogenesis).
2. Materials and methods
2.1. Reagents and recombinant proteins
Rabbit polyclonal anti-pSTAT3 and mouse monoclonal anti-α-
Tubulin antibodies were obtained from Cell Signaling. Rabbit
polyclonal anti-STAT3 antibody, HRP-conjugated goat anti-mouse
IgG, and anti-rabbit IgG were purchased from Santa Cruz Biotechnol-
ogy. Rabbit polyclonal anti-IL-6 antibody was obtained from Abcam.
FITC-conjugated donkey anti-rabbit IgG was purchased from Jackson
Immunoresearch. Matrigel and α-Cyano-(3,4-dihydroxy)-N-benzyl-
cinnamide (AG490) were from Calbiocam and BD Biotechnology,
respectively. Recombinant human IL-6 was obtained from R and D
systems. Recombinant human visfatin protein was prepared in our
laboratory as previously described [9]. Polymyxin B (PMB) was
obtained from Sigma.Fig. 1. JAK2-STAT3 signaling participates in visfatin-induced angiogenesis. (A, C) Rat aortic ri
presence or absence of AG490 (50 μM). Pictures are representative photographs for endoth
formation was quantiﬁed by counting the newly formed microvessels extending from the cu
with visfatin (5 μg/ml) and AG490 (50 μM) were injected into mice (B). The concentration o
(D). ⁎Pb0.01 compared to visfatin.2.2. Endothelial cell culture
Human dermal microvascular endothelial cells (HMECs) were
obtained from the Center for Disease Control (CDC) in Atlanta,
Georgia, USA. HMECs were maintained in MCDB 131 medium
(Invitrogen) supplemented with 10% FBS (Invitrogen), 1% antibiotics,
10mmol/l L-glutamine, 1 μg/ml hydrocortisone, and 10 ng/ml human
EGF at 37 °C under a humidiﬁed 95% to 5% (vol/vol) mixture of air and
CO2. Primary human umbilical vein endothelial cells (HUVECs)
(passages 5–8) were purchased from CLONECTICS. The HUVECs
were plated onto 3% gelatin-coated dish and grown in M199
(Invitrogen) with heat-inactivated 20% FBS, 3 ng/ml bFGF, and
100 μg/ml heparin.
2.3. Transient transfection of siRNA
We designed and synthesized a double stranded siRNA oligonu-
cleotide against STAT3 (5′-CAUCUGCCUAGAUCGGCUAdTdT-3′,3′-
dTdTGUAGACGGAUCUAGCCGAU-5′) and negative-control siRNA
was purchased from Bioneer. Oligofectamine (Invitrogen) was usedngs were embedded in Matrigel and cultured for 4 days with visfatin (500 ng/ml) in the
elial cell sprouts formed from the aortic ring segments (A). The degree of microvessel
ltured aortic rings (C). (B, D) Matrigel plugs were photographed. Matrigel plugs mixed
f hemoglobin was calculated from a parallel assay with a known amount of hemoglobin
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200 nM siRNA per 60 mm dish and 8 μl oligofectamine. HMECs were
transfected at 30% conﬂuence for 4 h with siRNA in minimal serum-
free mediumwithout antibiotics. Afterward, growthmedium contain-
ing 3× the normal concentration of serum was added without
removing the transfection mixture, and cells were allowed to grow an
additional 44 h until conﬂuent.
2.4. RNA extraction and RT-PCR analysis
Total RNA was harvest using TRIzol reagent (Invitrogen). cDNA
was synthesized using MMLV reverse transcriptase (Promega) with
2 μg of each DNA-free total RNA sample and oligo(dT) as primer,
according to the manufacturer's instructions. The oligonucleotide
primers for PCR were designed as follows: β-actin, 5′-GACTACCTCAT-
GAAGATC-3′ and 5′-GATCCACATCTGCTGGAA-3′; hIL-6, 5′-AGATTC-
CAAAGATGTAGCCG-3′ and 5′-TCTTTGCTGCTTTCACACAT-3′. RT-PCR
products of IL-6 and β-actin were 146 bp and 507 bp, respectively. The
ampliﬁcation proﬁle for IL-6 was 94 °C for 30 s, 57 °C for 30 s, and
72 °C for 30 s for 29 cycles. After the RT-PCR, the ampliﬁed products
were separated on a 1.8% (wt/vol) agarose gel and visualized by
ethidium bromide staining under UV light illumination.
2.5. Western immunoblot analysis
Harvested cells were lysed in a lysis buffer (40mMTris-Cl (pH 7.2),
10 mM EDTA, 120 mM NaCl, and 0.1% NP-40 with protease inhibitor
cocktail) and protein levels were measured by BCA assay. A constant
protein concentration (30 μg/lane) was used. The protein extracts
were boiled for 5 min, loaded, separated by SDS/PAGE and
transferred to a nitrocellulose membrane (Amersham Pharmacia
Biotech). The membranes were probed for a speciﬁc antibody binding
according to manufacturers' recommended protocols for the individ-
ual antibodies. Immunoreactive proteins were visualized using an
enhanced chemiluminescence (ECL) detection system (Amersham
Pharmacia Biotech).
2.6. Nuclear extraction and EMSA
To prepare nuclear protein extracts, HMECs were washed with
cold PBS (pH 7.4) and then immediately harvested by scraping. After
centrifugation of the cell suspension at 2000 rpm, the cell pellets
were lysed in cold buffer A (pH 7.5) containing 10mMHEPES, 1.5 mM
MgCl2, 10 mM NaCl, and 0.25% NP-40 for 5 min at 4 °C and then
centrifuged at 4000 rpm for 2 min to obtain a nuclear pellet. The
supernatant was removed and the nuclei pellets were resuspended in
cold buffer C (pH 7.5) containing 20 mM HEPES, 25% glycerol,
420 mM NaCl, 0.2 mM EDTA, 1.5 mM MgCl2, 10 mM NaCl, and 0.25%
NP-40; vigorously agitated from time to time; and then centrifuged
14000 rpm for 5 min. The supernatant containing the nuclearFig. 2. Visfatin activates endothelial STAT3. HMECs were preincubated with the
phosphatase inhibitor, NaF (5 mM) for 30 min prior to treatment with visfatin
(500 ng/ml) and polymyxin B (10 μg/ml) for the indicated times. (A) Protein levels
were examined byWestern immunoblot assay using anti-STAT3, anti-phosphotyrosine
(705)-STAT3, and anti-α-Tubulin antibodies. α-Tubulin served as the loading control.
(B) Immunocytochemical analysis of pSTAT3 localization. HMECs were grown on cover
slips and then stained with primary antibodies directed against pSTAT3 (Tyr705).
Following treatment with DAPI (blue nuclear stain) and ﬂuorescent secondary
antibodies for pSTAT3 (green), the cells were examined using ﬂuorescence microscopy.
Overlapping of the green (pSTAT3) and the blue (nucleus) colors indicates the
localization of activated STAT3 in the nuclei of HMECs. (C) The binding activity of STAT3
in nuclear extracts was measured by EMSA. Nuclear extracts from HMECs were
incubated with biotin-labeled STAT3 oligonucleotide as a probe. Arrow indicates the
migration of STAT3 protein−DNA complex (lanes 2, 3). Speciﬁcity is indicated by
competition analysis with ‘cold’ STAT3 probe. In the competition assay, 25- and 50-fold
molar excess unlabeled probe were added to the reaction mixtures (lanes 4, 5).proteins was diluted with cold buffer D (pH 7.5) containing 20 mM
HEPES, 50 mM KCl, 0.2 mM EDTA, 20% glycerol and used for the
EMSA. The STAT3 consensus oligonucleotide, 5′-GATCCTTCTGG-
GAATTCCTAGATC-3 was end labeled with biotin using a Biotin 3′
End DNA Labeling Kit (Pierce). Binding reactions containing equal
amounts of protein (1 μg) and biotin-labeled STAT3 oligonucleotide
(probe) were performed for 20 min in binding buffer (10 mM Tris–
HCl, 50 mM KCl, 5 mM MgCl2, 1 mM DTT, 0.05% NP-40, and 2.5%
glycerol). Binding reactions were analyzed using 6% native PAGE.
After blotting to a nylon membrane, labeled oligonucleotides were
detected with the Light Shift Chemiluminescent EMSA Kit following
the instructions of the manufacturer (Pierce). Competitors were
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cleotides, and were added at 25- and 50-fold molar excess to conﬁrm
the identities of the protein/DNA complexes.
2.7. ELISA
The amounts of IL-6 in media from HMECs stimulated with visfatin
were determined by speciﬁc enzyme-linked immunosorbent assay
(ELISA) according to themanufacturer's instructions (BioLegend). The
absorbance (450 nm) for each sample was analyzed using an ELISA
reader (EB800, Bio-Tek Instruments) and was interpolated with a
standard curve.
2.8. Immunocytochemistry
HMECs cultured on a coverglass were ﬁxed in 4% paraformal-
dehyde in PBS for 10 min and covered with ice-cold 100% methanol
for 10 min, then rinsed in PBS for 5 min. The cells were blocked
with 0.3% Triton X-100/5% normal goat serum/PBS for 60 min, and
then labeled with the primary antibody (rabbit polyclonal anti-
STAT3 antibody). After overnight incubation at 4 °C, the cells were
incubated with FITC-conjugated secondary antibody for 90 min.
Coverslips were mounted in Vectastain containing DAPI (Vector
Laboratories). Cells were analyzed using ﬂuorescence microscopy
(Nikon).Fig. 3. Visfatin upregulates IL-6 production. HMECs were incubated with 500 ng/ml of vi
(10 μg/ml). (A) Total RNAs were isolated and then analyzed by RT-PCR using speciﬁc prim
indicated relative gene expression of IL-6 was normalized to the internal control, β-actin.
against IL-6 and α-Tubulin antibodies. α-Tubulin served as the loading control. Quantitat
⁎Pb0.01 compared to control.2.9 In vitro tube formation assay
HMECs were seeded in medium containing 1% FBS in ultra low
attachment plates (6-well plates) and incubated with neutralizing
antibody against human IL-6 (200 μg/ml) for 1 h. 48-well culture
plates were coated with growth factor-reduced Matrigel in a total
volume of 130 μl per well and allowed to solidify for 30 min at 37 °C.
Cells in 6-well plates were transferred into the 48-well plates and
visfatin (500 ng/ml) was added to the each well. The plates incubated
for 8 h at 37 °C and morphological changes of the cells were
photographed under a microscope.
2.10. In vivo Matrigel plug assay
Angiogenesis was quantiﬁed by the matrigel plug assay as
previously described [10]. Brieﬂy, matrigel, in liquid from at 4 °C,
was mixed with visfatin (5 μg/ml) with and without AG490 (50 μM),
and resulting mixture was injected (0.5 ml) into the abdominal
subcutaneous tissue of 7-week-old male C57BL/6 mice, along the
peritoneal midline (4 mice/group). Mice were killed 7 days later, and
the matrigel plugs were removed and photographed. For hemoglobin
determination, the plugs were homogenized in 500 μl distilled water
andhemoglobin concentrationsweremeasured usingDrabkin reagent
kit 525 (Sigma) for the quantiﬁcation of blood vessel formation. All
animal studies were conducted in accordance with our institutionalsfatin for the indicated times. Culture medium was supplemented with polymyxin B
ers for human IL-6 and β-actin. Quantitative analysis is shown on the lower panel. The
(B) IL-6 protein levels were examined by Western immunoblot assay with antibodies
ive analysis of pSTAT3 normalized to the STAT3 expression is shown on right panel.
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Laboratory Animals published by the US National Institutes of Health
(NIH publication No. 85-23 revised 1996), and approved by the
Institutional Animal Care and Use Committee at Pusan National
University, Korea.
2.11. Ex vivo rat aortic ring assay
Male Sprague–Dawley rats (SD, 6 weeks of age), weighing 210–
230 g, were obtained from Samtako (Korea). The thoracic and
abdominal aortas were dissected from rats and excess perivascular
tissue was removed. Transverse sections (1–2 mm) were made, and
the resulting aortic rings were then washed in medium 199
(Invitrogen). The aorta rings were placed on Matrigel-coated wells,
covered with additional Matrigel, and allowed to gel for 30 min at
37 °C. Matrigel was allowed to congeal and was then covered with
conditioned medium. Embedded aortic rings were cultured at 37 °C,
5% CO2. On day 4, microvessel outgrowth was photographed under a
phase contrast microscope.
3. Results
3.1. The JAK2-STAT3 signaling pathway is involved in visfatin-induced
angiogenesis ex vivo and in vivo
In an initial screen of pharmacological inhibitors, AG490, a
speciﬁc inhibitor of JAK2-STAT3 signaling [23], inhibited visfatin-
induced angiogenesis in an ex vivo rat aorta model. Rat aortic rings
were placed on Matrigel and incubated with visfatin in the absence
or presence of AG490. Visfatin increased microvessel sprouting
∼5.5-fold from the adventitia of aortic rings, but AG490 inhibitedFig. 4. STAT3 signaling pathway participates in visfatin-induced IL-6 production. (A) HMECs
and polymyxin B (10 μg/ml). The activation state of STAT3 was determined byWestern imm
antibodies. α-Tubulin served as the loading control. (B) HMECs were preincubated with AG4
ml) for 24 h. The mRNA levels were analyzed by RT-PCR using speciﬁc primers for human IL-
ml) for 24 h in the presence or absence of AG490 (25 μM). Culture medium was supplement
ELISA. ⁎Pb0.01 compared to visfatin.this outgrowth (Fig. 1A, C). Similar results were obtained by in vivo
mouse Matrigel plug assay. Visfatin increased the hemoglobin
content of Matrigel plugs in mice, a measure of angiogenesis, and
AG490 blocked this increase (Fig. 1B, D). These results suggest that
JAK2-STAT3 signaling may mediate visfatin-induced angiogenesis ex
vivo and in vivo.
3.2. STAT3 is activated by visfatin in HMECs
To examine whether visfatin could activate STAT3 in endothelial
cells, we measured STAT3 phosphorylation on tyrosine 705 in human
microvessel endothelial cells (HMECs). Visfatin time-dependently
stimulated tyrosine phosphorylation of STAT3 with a peak at
60 minutes (∼2-fold) returning to basal levels by 180 min, but did
not change levels of total STAT3 or control protein (α-Tubulin)
(Fig. 2A). STAT3 phosphorylation determines the activation of STAT3,
and upon activation, STAT3 dimerizes and subsequently translocates
into the nucleus [24]. Thus, we examined the localization of pSTAT3 in
visfatin-treated cells by immunocytochemistry. Visfatin treatment
produced more STAT3-positive nuclei than controls (Fig. 2B). Active
STAT3 proteins in the nucleus bind to speciﬁc sequences on target
gene promoters to activate transcription [24]. Therefore, we checked
the DNA binding activity of STAT3 in nuclear extracts of visfatin-
treated cells by an electrophoretic mobility shift assay using biotin-
labeled oligonucleotides as a speciﬁc probe for the STAT3 binding site.
Visfatin stimulated the binding of nuclear extracts to the consensus
STAT3 binding sequence (Fig. 2C, lane 2 and 3). This STAT3-probe
complex was completely disrupted by competition with an unlabeled
probe (Fig. 2C, lane 4 and 5), indicating binding speciﬁcity. Taken
together, these results suggest that visfatin induces the activation of
STAT3 in human endothelial cells.were preincubated with AG490 (25 μM) for 1 h before exposure to visfatin (500 ng/ml)
unoblot assay using anti-STAT3, anti-phosphotyrosine (705)-STAT3 and anti-α-Tubulin
90 (25 μM) for 1 h before incubating with visfatin (500 ng/ml) and polymyxin B (10 μg/
6 and β-actin. (C, D) HMECs (C) and HUVECs (D) were incubated with visfatin (500 ng/
ed with polymyxin B (10 μg/ml). The amount of IL-6 protein secreted was measured by
Fig. 5. STAT3 mediates visfatin-induced IL-6 production. HMECs were transfected with
STAT3 siRNA (200 nM) or control siRNA (200 nM), according to the manufacturer's
instructions. (A) Cells were incubated with visfatin (500 ng/ml) and polymyxin B
(10 μg/ml) for 1 h before cell harvesting. The levels of STAT3 and pSTAT3 protein were
determined by Western immunoblot assay using anti-STAT3, anti-phospotyrosine
(705)-STAT3 and anti-α-Tubulin antibodies. α-Tubulin served as the loading control.
(B, C) Cells were incubated with visfatin (500 ng/ml) and polymyxin B (10 μg/ml) for
24 h before cell harvesting. Total RNAs were isolated and then analyzed by RT-PCR
using speciﬁc primers for human IL-6 and β-actin (B). β-actin served as an internal
control. The amount of IL-6 protein secreted was measured by ELISA(C). ⁎Pb0.01
compared to visfatin-treated control siRNA.
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IL-6, a multifunctional cytokine having angiogenic activity
[13,14], has been recently reported to be one of STAT3 target
genes [20,21]. Since, as shown in Fig. 2, STAT3 was activated by
visfatin, we speculated that IL-6 could be induced by visfatin
through the endothelial STAT3 activation. To test this possibility,
HMECs were treated with visfatin, and IL-6 mRNA levels were
analyzed by quantitative RT-PCR analysis. Visfatin upregulated the
levels of IL-6 mRNA by ∼25-fold in a time-dependent manner over
the untreated control (Fig. 3A). The levels of IL-6 protein in visfatin-
treated HMECs were further analyzed by Western immunoblot
analysis and ELISA. Consistent with the RT-PCR ﬁndings, IL-6 protein
levels were increased in cell lysates by ∼4.9-fold after visfatin
treatment (Fig. 3B). In addition, the release of IL-6 protein in the
culture medium was enhanced by visfatin treatment (Fig. 4C), which
corroborated the Western immunoblot analysis. Overall, these
ﬁndings show that visfatin upregulates IL-6 gene expression in
human endothelial cells.
3.4. STAT3 is involved in visfatin-induced IL-6 production in human
endothelial cells
To elucidate whether expression of phosphorylated STAT3 is
important for visfatin-induced IL-6 production, HMECs were pre-
incubated with AG490 followed by visfatin treatment and then the
levels of pSTAT3 protein, and IL-6 mRNA and protein were analyzed
by Western immunoblot analysis and/or RT-PCR. Indeed, AG490
efﬁciently blocked visfatin-induced STAT3 phosphorylation (Fig. 4A)
and impaired the induction of IL-6 gene expression by visfatin (Fig. 4B,
C) in HMECs, suggesting that STAT3 activated by visfatin may
contribute to IL-6 gene activation in human endothelial cells. Next,
to investigate whether the stimulating effect of visfatin-induced
STAT3 activation on IL-6 gene expression is dependent on endothelial
cell types, human umbilical vein endothelial cells (HUVECs) were
treated with visfatin in the presence or absence of AG490. Similarly,
visfatin upregulated IL-6 protein level in HUVECs, which was blocked
by AG490 (Fig. 4D), suggesting that mechanism(s) underlying
visfatin-induced IL-6 gene activation via STAT3 may be very similar
between microvascular EC and vein EC. Taken together, these results
suggest that IL-6 upregulation by visfatin may be attributable to
STAT3 activation in human endothelial cells.
3.5. STAT3 is required for visfatin-induced IL-6 production in human
endothelial cells
To further verify the role of STAT3 in mediating visfatin-induced
IL-6 gene activation, siRNA (short interference RNA) targeting for
STAT3 was used to knockdown STAT3 expression in HMECs. The
transfection of cells with STAT3 siRNA reduced both total STAT3
protein and visfatin-induced pSTAT3 levels (Fig. 5A), as well as the
subsequent increases in IL-6 mRNA and protein (Fig. 5B and C).
Overall, these ﬁndings show that STAT3 plays an important role in
mediating visfatin-induced IL-6 production in HMECs.
3.6. IL-6 is involved in visfatin-induced angiogenesis in vitro and ex vivo
To determine whether IL-6 is required for visfatin-induced
angiogenesis, we used anti-IL-6 neutralizing antibody to block IL-6
function in the in vitro tubular formation assay. Visfatin stimulated the
formation of a capillary-like network of endothelial cells on Matrigel,
but pretreatment with the neutralizing antibody blocked this activity
(Fig. 6A and C). The anti-IL-6 neutralizing antibody also blocked
visfatin-induced angiogenesis in an ex vivo aorta model of microvessel
sprouting (Fig. 6B and D). The neutralizing antibody could block the
activity of human recombinant IL-6 on aortic endothelial sprouting,validating its speciﬁcity. Taken together, these ﬁndings show that IL-6
mediates visfatin-induced angiogenesis in vitro and ex vivo.
4. Discussion
Recently, obesity has been considered to be a risk factor for tumor
growth, vascular inﬂammation, cardiovascular diseases including athe-
rosclerosis, and other angiogenic disorders [25,26] becausemany adipo-
kines including leptin, resistin, VEGF, FGF-2, and IL-6 have activity to
promote angiogenesis [6].We andothers have previously demonstrated
that the adipokine visfatin stimulates endothelial angiogenesis and
affects the expression of FGF-2 and VEGF genes in human endothelial
Fig. 6. IL-6 mediates visfatin-induced angiogenesis. (A, C) HMECs were incubated on theMatrigel with visfatin (500 ng/ml) after pretreatment with or without neutralizing antibody
against IL-6 (200 μg/ml) for 1 h. Capillary-like tube formationwas observed and photoswere taken at 8 h after cells were plated ontoMatrigel-coated plates (A). The quantitative tube
formation assays are shown in the lower panel. The average numbers of tubule branch pointswere quantiﬁed (C). (B, D) Rat aortic ringswere embedded intoMatrigel and then treated
with a combination of visfatin (500 ng/ml) and neutralizing antibody against IL-6 (400 μg/ml). Recombinant human IL-6 protein (50 ng/ml) was used as a positive control. On day 4,
endothelial cell sprouts formed from the aortic ring segments were photographed using a phase contrast microscope (B). Quantitation of newly formed microvessels is shown in the
lower panel. The total length of capillary-like tube was measured and normalized with controls (D). ⁎⁎Pb0.05, ⁎Pb0.01 compared to visfatin, #Pb0.01 compared to rh-IL-6.
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the activation of STAT3 and upregulates endothelial IL-6 expression; (2)
Blockade of STAT3 signaling inhibits visfatin-induced IL-6 expression;
(3) Neutralization of IL-6 function suppresses visfatin-induced angio-
genesis. Taken together, these ﬁndings show that STAT3 plays an
important role in the induction of IL-6 by visfatin in human endothelial
cells and reveal that IL-6 mediates visfatin-induced angiogenesis.
IL-6 is produced by various cells such as lymphocytes, synovial
ﬁbroblasts, macrophages, amniotic epithelial cells, tumor cells, andendothelial cells [16,17]. The released IL-6 form a complexwith the IL-
6 receptor (IL-6R), which is composed of IL-6Rα gp80 and the
coreceptor gp130 and then activate JAK to phosphorylate tyrosine 705
on STAT3 [27]. The phosphorylated STAT3 (pSTAT3) dimerizes,
subsequently translocates into the nucleus, and activates the
transcription of its target genes [24,27], thereby regulating cell
proliferation, differentiation, adhesion, migration, and apoptosis/
survival [28]. However, in light of mounting evidence for the
downstream signaling pathways of IL-6 and its role in various cells
1766 J.-Y. Kim et al. / Biochimica et Biophysica Acta 1793 (2009) 1759–1767including endothelial cells, little is known in regard to the mechanism
of endothelial IL-6 gene induction. Here, we found that visfatin-
activated STAT3 participates in the upregulation of IL-6 gene
expression in human endothelial cells (Figs. 4 and 5). The role of
STAT3 in the induction of IL-6 is further supported by other previous
reports that phosphatidic acid can induce IL-6 synthesis through
STAT3 activation in macrophages [20], and cardiotropin-1 activates
STAT3 to increase IL-6 production in HUVECs [21]. The stimulating
effect of visfatin on human IL-6 gene transcription via STAT3 was
conﬁrmed by human IL-6 gene promoter-driven reporter assay (data
not shown). We used a reporter plasmid containing a 651-bp
fragment of the human IL-6 gene promoter located directly upstream
of the transcriptional start site and performed reporter assay after
transfection of the plasmid into HMECs. In this preliminary study, we
found that visfatin induced activation of a reporter plasmid containing
a 651-bp fragment of the human IL-6 gene promoter located directly
upstream of the transcriptional start site, and this could be blocked by
AG490 (data not shown), suggesting that promoter activity of IL-6
gene is under the control of JAK2-STAT3 in HMECs, although it is
unclear whether this control is mediated by direct binding of STAT3
on IL-6 promoter or indirectly.
We and others reported that PI3K, p38 MAPK, and ERK1/2
signaling pathways contribute to visfatin-induced angiogenesis
[9,11,12,29] and showed that the NF-kB pathway is involved in
visfatin activity [30-32]. We also observed that these pathways
mediate IL-6 gene induction by visfatin in human endothelial cells
(data not shown), consistent with a recent report [33]. Besides these
pathways, in this study, our results add a new one, STAT3 signaling
pathway, to the list of molecular mechanisms leading to visfatin-
induced IL-6 upregulation (Figs. 4 and 5) and angiogenesis (Fig. 1).
STAT3 regulates cell proliferation and migration, and mediates
vascular function. Furthermore, STAT3 is constitutively activated in
many tumor cells and contributes to tumor cell proliferation and
survival [22,34]. Therefore, considering the activity of visfatin to
activate STAT3 (Fig. 2) and to induce angiogenesis (Figs. 1 and 5), it is
likely that visfatin is able to promote the growth of cancer cells
through the STAT3 activation, and can stimulate angiogenesis,
potentially leading to tumorigenesis and tumor angiogenesis in
STAT3-dependent human cancers, including gliomas and human
breast tumors [35,36]. Supporting this, the role of visfatin in the
development or progression of these cancers has been suggested by a
recent report showing that visfatin serum levels were substantially
elevated in many of astrocytoma and glioblastomas patients [37] and
by our previous ﬁndings of strong visfatin immunostaining in human
breast cancer tissues [38]. In addition, obesity has been reported to be
a strong risk factor for many cancers including breast cancer [39].
Based on these ﬁndings, it appears that visfatin-STAT3 signaling
functions as an important pathway operational in the pathogenesis of
breast cancer disease in obese patients. This possibility is currently
under investigation.
It is well known that IL-6 acts as a key proinﬂammatory cytokine to
mediate both innate and acquired immune responses and has been
linked to many kinds of inﬂammatory and cardiovascular diseases,
including atherosclerosis, rheumatoid arthritis, diabetes, osteoporo-
sis, and cancers [16,17,40]. Thus, the marked induction of IL-6 by
visfatin suggests that visfatin could be an important modulator in
these IL-6-related physiologic and/or pathophysiologic conditions.
Indeed, recent evidence has shown that visfatin expression is highly
detected in a variety of acute and chronic inﬂammatory diseases
including sepsis, rheumatoid arthritis, inﬂammatory bowel disease,
myocardial infarction, and atherosclerosis [41]. Considering that
aberrant expression of IL-6 reportedly induces endothelial activation
and leads to inﬂammation and vascular diseases [42], it is conceivable
that visfatin could contribute to vascular inﬂammatory state,
cardiovascular disease, and cancers, at least in part, by stimulating
IL-6 gene expression. Therefore, our results in this study suggest thatvisfatin may aid in the development of these IL-6-associated
physiologic and/or pathophysiologic conditions through positive
feedback control of STAT3 activation, which is initially induced by
visfatin and later by IL-6; namely, visfatin-STAT3-IL-6-STAT3. In this
aspect, it will be interesting to study whether visfatin-STAT3-IL-6
signaling axis could be a new potential therapeutic target in these
IL-6-associated diseases.
Recent studies have reported the role of visfatin-induced IL-6 in
mediating anti-apoptosis [43]. For example, visfatin upregulates IL-6
protein level, which activates STAT3 signaling by binding of the IL-6 to
IL-6 receptor, thereby protecting macrophages from ER stress-
induced apoptosis [43]. Therefore, it is likely that visfatin-induced
IL-6 may play a role in enhancing endothelial cell survival as well as in
promoting angiogenic response.
Besides on IL-6, the stimulatory effects of visfatin on angiogenic
factors have been recently reported by us and other investigators
[10-12]. Production of human endothelial FGF-2 has been shown to
increase after the treatment of visfatin [12]. In addition, VEGF levels
were increased in visfatin-treated human endothelial cells [11].
Thus, visfain can be considered as a new proangiogenic adipokine,
which is able to induce potent angiogenic factors, including FGF-2,
VEGF and IL-6.
In summary, our ﬁndings provide the ﬁrst example of STAT3-
dependent endothelial IL-6 induction by visfatin and of the role of IL-6
in mediating visfatin-induced angiogenesis. These results provide
novel insights into the mechanisms of vascular pathologies and new
opportunities for therapeutic intervention by targeting visfatin/
STAT3/IL-6 signaling axis.
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